View Future GrowthNeuRizer 과거 순이익 실적과거 기준 점검 0/6NeuRizer의 수입은 연평균 -7.4%의 비율로 감소해 온 반면, Chemicals 산업의 수입은 연간 0.5% 증가했습니다.핵심 정보-7.37%순이익 성장률9.38%주당순이익(EPS) 성장률Chemicals 산업 성장률14.45%매출 성장률n/a자기자본이익률-7.67%순이익률n/a최근 순이익 업데이트30 Jun 2024최근 과거 실적 업데이트업데이트 없음모든 업데이트 보기Recent updates공시 • Feb 21NeuRizer Ltd. has completed a Follow-on Equity Offering in the amount of AUD 0.2 million.NeuRizer Ltd. has completed a Follow-on Equity Offering in the amount of AUD 0.2 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 133,333,333 Price\Range: AUD 0.0015 Transaction Features: Subsequent Direct Listing공시 • Feb 18NeuRizer Ltd. has filed a Follow-on Equity Offering in the amount of AUD 0.2 million.NeuRizer Ltd. has filed a Follow-on Equity Offering in the amount of AUD 0.2 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 133,333,333 Price\Range: AUD 0.0015 Transaction Features: Subsequent Direct Listing공시 • Feb 08NeuRizer Ltd. has completed a Follow-on Equity Offering in the amount of AUD 0.3068 million.NeuRizer Ltd. has completed a Follow-on Equity Offering in the amount of AUD 0.3068 million. Security Name: Oridnary Shares Security Type: Common Stock Securities Offered: 159,800,000 Price\Range: AUD 0.001 Security Name: Oridnary Shares Security Type: Common Stock Securities Offered: 147,000,000 Price\Range: AUD 0.001 Transaction Features: Subsequent Direct ListingBoard Change • Feb 04No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Non-Executive Director Manyoo Han was the last director to join the board, commencing their role in 2024. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.공시 • Jan 22NeuRizer Ltd. has completed a Follow-on Equity Offering in the amount of AUD 0.15 million.NeuRizer Ltd. has completed a Follow-on Equity Offering in the amount of AUD 0.15 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 100,000,000 Price\Range: AUD 0.0015 Transaction Features: Subsequent Direct ListingBoard Change • Dec 24No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Non-Executive Director Manyoo Han was the last director to join the board, commencing their role in 2024. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.공시 • Dec 11NeuRizer Ltd. has filed a Follow-on Equity Offering in the amount of AUD 0.3068 million.NeuRizer Ltd. has filed a Follow-on Equity Offering in the amount of AUD 0.3068 million. Security Name: Oridnary Shares Security Type: Common Stock Securities Offered: 306,800,000 Price\Range: AUD 0.001 Transaction Features: Subsequent Direct Listing공시 • Oct 30NeuRizer Ltd., Annual General Meeting, Nov 28, 2024NeuRizer Ltd., Annual General Meeting, Nov 28, 2024.New Risk • Jul 17New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: AU$14.3m (US$9.62m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$13m free cash flow). Share price has been highly volatile over the past 3 months (54% average weekly change). Earnings have declined by 17% per year over the past 5 years. Shareholders have been substantially diluted in the past year (53% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (AU$14.3m market cap, or US$9.62m).New Risk • May 26New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 60% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$13m free cash flow). Share price has been highly volatile over the past 3 months (42% average weekly change). Earnings have declined by 17% per year over the past 5 years. Shareholders have been substantially diluted in the past year (60% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (AU$3.80m market cap, or US$2.52m).Board Change • Apr 15No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Company Secretary & Non-Executive Director Jordan Mehrtens was the last director to join the board, commencing their role in 2024. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.공시 • Feb 12NeuRizer Ltd. Appoints Jordan Mehrtens as Non-Executive DirectorNeuRizer Ltd. announce that Ms Jordan Mehrtens has been appointed as a non-executive Director of the Company, effective 11 February 2024. Ms Mehrtens is the Company Secretary and has been for the past 9 years, with the key terms of her employment agreement detailed below. Ms Mehrtens is a qualified Lawyer and has a Bachelor of Commerce (Finance) and a Graduate Diploma in Urban and Regional Planning. Ms Mehrtens has worked with the NeuRizer Urea Project since its commencement, providing regulatory, compliance and other analytical advice. Ms Mehrtens is a member of the Governance Institute of Australia (GIA) and holds a Certificate in Governance Practice from the GIA.New Risk • Jan 18New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Australian stocks, typically moving 21% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (21% average weekly change). Earnings have declined by 25% per year over the past 5 years. Earnings have declined by 25% per year over the past 5 years. Revenue is less than US$1m. Revenue is less than US$1m. Market cap is less than US$10m (AU$9.65m market cap, or US$6.34m). Minor Risks Shareholders have been diluted in the past year (24% increase in shares outstanding). Shareholders have been diluted in the past year (24% increase in shares outstanding).공시 • Jan 16Neurizer Ltd. Announces Executive ChangesNeuRizer Ltd. announced that as a result of a corporate review the position of Managing Director has been made redundant. The Executive Chairman will assume the duties previously undertaken by the Managing Director. Assuch Phil Staveley will cease being the Managing Director of NRZ on the 15th of January 2024.공시 • Dec 20NeuRizer Ltd. Announces Step Down of Murray Chatfield from the BoardNeuRizer Ltd. advised that after more than 7 years as non-executive director, Mr. Murray Chatfield has decided to step down from the NeuRizer Board effective immediately. Murray joined the board in 2015 as an independent director. In that time he has provided valuable input and guidance to the Company. His endless energy, vast knowledge of financial markets and products combined with a passion for relevant targeted innovation has been a valuable and deep resource for NeuRizer. Murray attended every board and audit committee meeting over his 7 years and has always worked to ensure that the best interests of shareholders were at the forefront in the decision making of the Company.New Risk • Nov 10New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Australian stocks, typically moving 13% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 25% per year over the past 5 years. Revenue is less than US$1m. Minor Risks Share price has been volatile over the past 3 months (13% average weekly change). Shareholders have been diluted in the past year (17% increase in shares outstanding). Market cap is less than US$100m (AU$34.5m market cap, or US$21.9m).공시 • Oct 11NeuRizer Ltd., Annual General Meeting, Nov 10, 2023NeuRizer Ltd., Annual General Meeting, Nov 10, 2023, at 09:30 Cen. Australia Standard Time. Agenda: To consider the financial report and the reports of the Directors and of the Auditors for the financial year ended 30 June 2023; to consider adoption of the Remuneration Report for the year ended 30 June 2023; to consider re-election of Directors of the Company; to consider approval to issue Placement Shares; to consider ratification of the issue of shares for March and September Placement Shares; to consider ratification of the issue of options to March Broker Options; to consider Issue of Options to Zhe Wang, Zheng Xiaojiang and Murray Chatfield in lieu of pay; and to consider approval of additional 10% Placement Capacity.New Risk • Oct 02New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 28% per year over the past 5 years. Revenue is less than US$1m. Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Shareholders have been diluted in the past year (21% increase in shares outstanding). Market cap is less than US$100m (AU$47.0m market cap, or US$30.2m).공시 • Sep 06NeuRizer Ltd. has completed a Follow-on Equity Offering in the amount of AUD 1 million.NeuRizer Ltd. has completed a Follow-on Equity Offering in the amount of AUD 1 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 20,000,000 Price\Range: AUD 0.05 Transaction Features: Subsequent Direct Listing공시 • Aug 01NeuRizer Ltd. Announces Change of DirectorsNeuRizer Ltd. announced that Mr. Sunghun Ryu has been appointed as a Non-Executive Director of the Company, effective 31 July 2023. This follows the resignation of Mr. Jaehyung Yoo from the Board of NRZ. Mr. Yoo joined the NRZ Board in August 2022 and has resigned due to a change in Mr. Yoo's role at DL E&C Co. Ltd. (DL E&C). Mr. Ryu is the Vice President of Strategy & Planning, Plant Business Division of DL E&C.Recent Insider Transactions • Jun 09MD & Director recently sold AU$194k worth of stockOn the 1st of June, Phillip Staveley sold around 2m shares on-market at roughly AU$0.097 per share. This transaction amounted to 25% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was Phillip's only on-market trade for the last 12 months.공시 • May 10NeuRizer Ltd. has completed a Follow-on Equity Offering in the amount of AUD 1 million.NeuRizer Ltd. has completed a Follow-on Equity Offering in the amount of AUD 1 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 14,285,714 Price\Range: AUD 0.07 Transaction Features: Subsequent Direct ListingBoard Change • Mar 01Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Non-Executive Independent Director Wang Zhe was the last independent director to join the board, commencing their role in 2017. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.매출 및 비용 세부 내역NeuRizer가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이CHIA:NRZ 매출, 비용 및 순이익 (AUD Millions)날짜매출순이익일반관리비연구개발비30 Jun 240-61031 Mar 240-73031 Dec 230-84030 Sep 230-127030 Jun 230-1610031 Mar 230-1910031 Dec 220-2210030 Sep 220-219030 Jun 220-208031 Mar 220-199031 Dec 210-189030 Sep 210-168030 Jun 210-147031 Mar 210-116031 Dec 200-85030 Sep 200-85030 Jun 200-74031 Mar 200-84031 Dec 190-84030 Sep 190-94030 Jun 190-105031 Mar 190-95031 Dec 180-85030 Sep 180-74030 Jun 180-64031 Mar 180-63031 Dec 170-53030 Sep 170-64030 Jun 170-64031 Mar 170-63031 Dec 160-63030 Sep 160-63030 Jun 160-53031 Mar 160-123031 Dec 150-193030 Sep 150-192030 Jun 150-181030 Jun 140000양질의 수익: NRZ 은(는) 현재 수익성이 없습니다.이익 마진 증가: NRZ는 현재 수익성이 없습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: NRZ은 수익성이 없으며 지난 5년 동안 손실이 연평균 7.4% 증가했습니다.성장 가속화: 현재 수익성이 없어 지난 1년간 NRZ의 수익 성장률을 5년 평균과 비교할 수 없습니다.수익 대 산업: NRZ은 수익성이 없어 지난 해 수익 성장률을 Chemicals 업계(5.8%)와 비교하기 어렵습니다.자기자본이익률높은 ROE: NRZ는 현재 수익성이 없으므로 자본 수익률이 음수(-7.67%)입니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YMaterials 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2025/06/11 03:37종가2025/03/14 00:00수익2024/06/30연간 수익2024/06/30데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스NeuRizer Ltd.는 2명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Sanjeev BahlEdison Investment ResearchStuart RobertsPitt Street Research Pty Ltd.
공시 • Feb 21NeuRizer Ltd. has completed a Follow-on Equity Offering in the amount of AUD 0.2 million.NeuRizer Ltd. has completed a Follow-on Equity Offering in the amount of AUD 0.2 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 133,333,333 Price\Range: AUD 0.0015 Transaction Features: Subsequent Direct Listing
공시 • Feb 18NeuRizer Ltd. has filed a Follow-on Equity Offering in the amount of AUD 0.2 million.NeuRizer Ltd. has filed a Follow-on Equity Offering in the amount of AUD 0.2 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 133,333,333 Price\Range: AUD 0.0015 Transaction Features: Subsequent Direct Listing
공시 • Feb 08NeuRizer Ltd. has completed a Follow-on Equity Offering in the amount of AUD 0.3068 million.NeuRizer Ltd. has completed a Follow-on Equity Offering in the amount of AUD 0.3068 million. Security Name: Oridnary Shares Security Type: Common Stock Securities Offered: 159,800,000 Price\Range: AUD 0.001 Security Name: Oridnary Shares Security Type: Common Stock Securities Offered: 147,000,000 Price\Range: AUD 0.001 Transaction Features: Subsequent Direct Listing
Board Change • Feb 04No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Non-Executive Director Manyoo Han was the last director to join the board, commencing their role in 2024. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
공시 • Jan 22NeuRizer Ltd. has completed a Follow-on Equity Offering in the amount of AUD 0.15 million.NeuRizer Ltd. has completed a Follow-on Equity Offering in the amount of AUD 0.15 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 100,000,000 Price\Range: AUD 0.0015 Transaction Features: Subsequent Direct Listing
Board Change • Dec 24No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Non-Executive Director Manyoo Han was the last director to join the board, commencing their role in 2024. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
공시 • Dec 11NeuRizer Ltd. has filed a Follow-on Equity Offering in the amount of AUD 0.3068 million.NeuRizer Ltd. has filed a Follow-on Equity Offering in the amount of AUD 0.3068 million. Security Name: Oridnary Shares Security Type: Common Stock Securities Offered: 306,800,000 Price\Range: AUD 0.001 Transaction Features: Subsequent Direct Listing
공시 • Oct 30NeuRizer Ltd., Annual General Meeting, Nov 28, 2024NeuRizer Ltd., Annual General Meeting, Nov 28, 2024.
New Risk • Jul 17New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: AU$14.3m (US$9.62m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$13m free cash flow). Share price has been highly volatile over the past 3 months (54% average weekly change). Earnings have declined by 17% per year over the past 5 years. Shareholders have been substantially diluted in the past year (53% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (AU$14.3m market cap, or US$9.62m).
New Risk • May 26New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 60% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$13m free cash flow). Share price has been highly volatile over the past 3 months (42% average weekly change). Earnings have declined by 17% per year over the past 5 years. Shareholders have been substantially diluted in the past year (60% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (AU$3.80m market cap, or US$2.52m).
Board Change • Apr 15No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Company Secretary & Non-Executive Director Jordan Mehrtens was the last director to join the board, commencing their role in 2024. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
공시 • Feb 12NeuRizer Ltd. Appoints Jordan Mehrtens as Non-Executive DirectorNeuRizer Ltd. announce that Ms Jordan Mehrtens has been appointed as a non-executive Director of the Company, effective 11 February 2024. Ms Mehrtens is the Company Secretary and has been for the past 9 years, with the key terms of her employment agreement detailed below. Ms Mehrtens is a qualified Lawyer and has a Bachelor of Commerce (Finance) and a Graduate Diploma in Urban and Regional Planning. Ms Mehrtens has worked with the NeuRizer Urea Project since its commencement, providing regulatory, compliance and other analytical advice. Ms Mehrtens is a member of the Governance Institute of Australia (GIA) and holds a Certificate in Governance Practice from the GIA.
New Risk • Jan 18New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Australian stocks, typically moving 21% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (21% average weekly change). Earnings have declined by 25% per year over the past 5 years. Earnings have declined by 25% per year over the past 5 years. Revenue is less than US$1m. Revenue is less than US$1m. Market cap is less than US$10m (AU$9.65m market cap, or US$6.34m). Minor Risks Shareholders have been diluted in the past year (24% increase in shares outstanding). Shareholders have been diluted in the past year (24% increase in shares outstanding).
공시 • Jan 16Neurizer Ltd. Announces Executive ChangesNeuRizer Ltd. announced that as a result of a corporate review the position of Managing Director has been made redundant. The Executive Chairman will assume the duties previously undertaken by the Managing Director. Assuch Phil Staveley will cease being the Managing Director of NRZ on the 15th of January 2024.
공시 • Dec 20NeuRizer Ltd. Announces Step Down of Murray Chatfield from the BoardNeuRizer Ltd. advised that after more than 7 years as non-executive director, Mr. Murray Chatfield has decided to step down from the NeuRizer Board effective immediately. Murray joined the board in 2015 as an independent director. In that time he has provided valuable input and guidance to the Company. His endless energy, vast knowledge of financial markets and products combined with a passion for relevant targeted innovation has been a valuable and deep resource for NeuRizer. Murray attended every board and audit committee meeting over his 7 years and has always worked to ensure that the best interests of shareholders were at the forefront in the decision making of the Company.
New Risk • Nov 10New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Australian stocks, typically moving 13% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 25% per year over the past 5 years. Revenue is less than US$1m. Minor Risks Share price has been volatile over the past 3 months (13% average weekly change). Shareholders have been diluted in the past year (17% increase in shares outstanding). Market cap is less than US$100m (AU$34.5m market cap, or US$21.9m).
공시 • Oct 11NeuRizer Ltd., Annual General Meeting, Nov 10, 2023NeuRizer Ltd., Annual General Meeting, Nov 10, 2023, at 09:30 Cen. Australia Standard Time. Agenda: To consider the financial report and the reports of the Directors and of the Auditors for the financial year ended 30 June 2023; to consider adoption of the Remuneration Report for the year ended 30 June 2023; to consider re-election of Directors of the Company; to consider approval to issue Placement Shares; to consider ratification of the issue of shares for March and September Placement Shares; to consider ratification of the issue of options to March Broker Options; to consider Issue of Options to Zhe Wang, Zheng Xiaojiang and Murray Chatfield in lieu of pay; and to consider approval of additional 10% Placement Capacity.
New Risk • Oct 02New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 28% per year over the past 5 years. Revenue is less than US$1m. Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Shareholders have been diluted in the past year (21% increase in shares outstanding). Market cap is less than US$100m (AU$47.0m market cap, or US$30.2m).
공시 • Sep 06NeuRizer Ltd. has completed a Follow-on Equity Offering in the amount of AUD 1 million.NeuRizer Ltd. has completed a Follow-on Equity Offering in the amount of AUD 1 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 20,000,000 Price\Range: AUD 0.05 Transaction Features: Subsequent Direct Listing
공시 • Aug 01NeuRizer Ltd. Announces Change of DirectorsNeuRizer Ltd. announced that Mr. Sunghun Ryu has been appointed as a Non-Executive Director of the Company, effective 31 July 2023. This follows the resignation of Mr. Jaehyung Yoo from the Board of NRZ. Mr. Yoo joined the NRZ Board in August 2022 and has resigned due to a change in Mr. Yoo's role at DL E&C Co. Ltd. (DL E&C). Mr. Ryu is the Vice President of Strategy & Planning, Plant Business Division of DL E&C.
Recent Insider Transactions • Jun 09MD & Director recently sold AU$194k worth of stockOn the 1st of June, Phillip Staveley sold around 2m shares on-market at roughly AU$0.097 per share. This transaction amounted to 25% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was Phillip's only on-market trade for the last 12 months.
공시 • May 10NeuRizer Ltd. has completed a Follow-on Equity Offering in the amount of AUD 1 million.NeuRizer Ltd. has completed a Follow-on Equity Offering in the amount of AUD 1 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 14,285,714 Price\Range: AUD 0.07 Transaction Features: Subsequent Direct Listing
Board Change • Mar 01Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Non-Executive Independent Director Wang Zhe was the last independent director to join the board, commencing their role in 2017. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.